CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

nintedanib

Last Updated: August 14, 2020
Result type: Reports
Project Number: SR0654-000
Product Line: Common Drug Review

Generic Name: nintedanib

Brand Name: Ofev

Manufacturer: Boehringer Ingelheim (Canada) Ltd.

Indications: chronic fibrosing interstitial lung diseases

Manufacturer Requested Reimbursement Criteria1: As per the Health Canada approved indication for progressive fibrosing-ILD (PF-ILD).

Submission Type: New

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input openJune 25, 2020
Call for patient input closedAugust 17, 2020
Submission receivedJuly 24, 2020
Submission acceptedAugust 13, 2020
Clarification:

- Submission was not accepted for review on 10 Aug 2020

Review initiatedAugust 14, 2020
Draft CADTH review report(s) provided to sponsor for commentOctober 29, 2020
Deadline for sponsors commentsNovember 09, 2020
CADTH responses on draft review report(s) provided to sponsorJanuary 08, 2021
Expert committee meeting (initial)January 20, 2021
Draft recommendation issuedFebruary 01, 2021
To
February 03, 2021
Submit Feedback